News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
A shareholder of Royalty Pharma plc (RPRX) has filed a Form 144 to sell 125,000 Class A ordinary shares on NASDAQ through J.P. Morgan Securities LLC, with an indicated aggregate market value of $7,223,750. The filing, dated August 12, 2026, notes the planned sale …
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Zealand Pharma stock has delivered a strong 90.3% return over the past five years, yet its low overall value score and current market multiples suggest the shares …
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Why Zealand Pharma stock is in focus after the Royalty Pharma deal Zealand Pharma (CPSE:ZEAL) has drawn fresh attention after agreeing to a US$100 million royalty purchase …
Royalty Pharma plc (RPRX) has filed a Form 144 notice indicating a proposed sale of up to 11,925,082 Class A ordinary shares through J.P. Morgan Securities LLC on NASDAQ. These shares were acquired through various means, including a significant block from a Conversion of …
Royalty Pharma plc NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $100 million in funding to Zealand Pharma in exchange for Zealand Pharma's economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia …
Zealand Pharma Company announcement – No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide Zealand Pharma will receive USD 100 million for the sale of its economic …
Pablo G. Legorreta, CEO and Chairman of Royalty Pharma (RPRX), received an exempt award of 65,216 Class A Ordinary Shares as settlement for Equity Performance Awards, increasing his direct holdings to 1,307,820 shares. He also made a bona fide gift of 30,000 LP interests …
Royalty Pharma EVP Urist Marshall received 8,252 Class A Ordinary Shares as an exempt award and gifted 3,000 limited partnership interests, which are exchangeable into 30,000 Class A shares. Marshall also holds indirect Class A shares through an IRA and Class E Ordinary Shares …
Christopher Hite, EVP & Chairman, Partnering at Royalty Pharma (NASDAQ: RPRX), was awarded 11,002 Class A Ordinary Shares on August 5, 2026, as part of an exempt grant connected to the settlement of Equity Performance Awards. This transaction increased the indirect holdings through SCH …
Royalty Pharma plc CFO Terrance P. Coyne reported an acquisition of 11,002 Class A Ordinary Shares through an exempt settlement of Equity Performance Awards and an indirect bona fide gift of 18,500 Class E Ordinary Shares. Following the gift, Coyne indirectly holds 1,788,777 Class …
This article first appeared on GuruFocus. Cash and Investments: $3.9 billion at the end of Q2 2026, including $2.2 billion in gross proceeds from public offerings and a $250 million royalty tranche from Royalty Pharma. R&D Expenses: $395 million in Q2 2026, up from …
For the quarter ended June 2026, Royalty Pharma (RPRX) reported revenue of $773 million, up 6.3% over the same period last year. EPS came in at $1.32, compared to $1.14 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of …
Royalty Pharma (RPRX) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.14 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …
(RTTNews) - Royalty Pharma plc (RPRX) will host a conference call at 8:00 AM ET on August 5, 2026, to discuss Q2 26 earnings results. To access the live webcast, log on to https://www.royaltypharma.com/investors/events/ The views and opinions expressed herein are the views and …
Analysts on Wall Street project that Royalty Pharma (RPRX) will announce quarterly earnings of $1.27 per share in its forthcoming report, representing an increase of 11.4% year over year. Revenues are projected to reach $761.4 million, increasing 4.7% from the same quarter last year. …
Royalty Pharma plc NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Greg Raskin, M.D. as Senior Vice President, Head of Academic Initiatives, effective August 2026. Greg will lead Royalty Pharma's outreach efforts with academic …
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Royalty Pharma dividend decision puts income focus in the spotlight Royalty Pharma (RPRX) has affirmed a third quarter 2026 dividend of $0.235 per Class …
(RTTNews) - The following biotech stocks reached a 52-week high on July 29, 2026, driven by key catalysts such as the release of second quarter financial results and ongoing clinical research. Anika Therapeutics Inc. (ANIK) Anika Therapeutics is a joint preservation company, specializing in …
The market expects Royalty Pharma (RPRX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might …
This article displays the total equity of Royalty Pharma Plc Class A (HAM:RPD) on the Hamburg Stock Exchange. It provides a snapshot of the company's financials through TradingView, indicating that the market was closed with no trades at the time of viewing. The content …
Search by ticker symbol or company name and select a result to open its chart.